Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
grade F 8.3 1.16% 0.10
MGNX closed down 0.55 percent on Wednesday, November 13, 2019, on 72 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical MGNX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.16%
Oversold Stochastic Weakness 1.16%
MACD Bullish Signal Line Cross Bullish 0.61%
Wide Bands Range Expansion 0.61%
Oversold Stochastic Weakness 0.61%
New 52 Week Closing Low Bearish 4.53%
Expansion Breakdown Bearish Swing Setup 4.53%
New 52 Week Low Weakness 4.53%
Wide Bands Range Expansion 4.53%
Oversold Stochastic Weakness 4.53%

Older signals for MGNX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Treatment Of Cancer Antibodies Immune System Autoimmune Diseases Monoclonal Antibodies Antibody Technology Platforms Novel Cancer
Is MGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 12 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SNDL, MGNX and OLLI
Nov 12 FILING FIRM ANNOUNCES DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses to Contact the Firm
Nov 12 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MGNX, OSTK, RUHN and REZI
Nov 12 TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Nov 12 CLASS ACTION UPDATE for SNDL, DBX, MGNX and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Nov 12 MGNX DEADLINE TODAY: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts MacroGenics (MGNX) Investors of Today’s Deadline to Move for Lead Plaintiff
Nov 11 CLASS ACTION UPDATE for SNDL, MGNX and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Nov 11 MacroGenics Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm
Nov 11 FILING FIRM ANNOUNCES DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses to Contact the Firm
Nov 11 SHAREHOLDER ALERT: UNIT MGNX QUAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
See more MGNX news...
Indicators
Indicator Value
52 Week High 32.32
52 Week Low 7.88
Average Volume 492,230
200-Day Moving Average 15.6263
50-Day Moving Average 11.187
20-Day Moving Average 9.103
10-Day Moving Average 8.3845
Average True Range 0.5296
ADX 51.51
+DI 8.4002
-DI 29.303
Chandelier Exit (Long, 3 ATRs ) 10.0912
Chandelier Exit (Short, 3 ATRs ) 9.4688
Upper Bollinger Band 11.3049
Lower Bollinger Band 6.9011
Percent B (%b) 0.3
BandWidth 48.377458
MACD Line -0.9177
MACD Signal Line -0.9676
MACD Histogram 0.0499
Fundamentals Value
Market Cap 301.93 Million
Num Shares 36.8 Million
EPS -4.19
Price-to-Earnings (P/E) Ratio -1.96
Price-to-Sales 56.93
Price-to-Book 2.96
PEG Ratio 0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.82
Resistance 3 (R3) 8.85 8.67 8.72
Resistance 2 (R2) 8.67 8.51 8.66 8.68
Resistance 1 (R1) 8.44 8.41 8.55 8.41 8.65
Pivot Point 8.26 8.26 8.32 8.25 8.26
Support 1 (S1) 8.03 8.10 8.14 8.00 7.76
Support 2 (S2) 7.85 8.00 7.84 7.73
Support 3 (S3) 7.62 7.85 7.69
Support 4 (S4) 7.59